Related Experiment Videos
Myasthenia gravis during pregnancy.
Simone Ferrero1, Francesca Esposito, Mariangela Biamonti
1Department of Obstetrics & Gynecology, San Martino Hospital & University of Genoa, Largo R. Benzi 1, 16132, Genoa, Italy. dr@simoneferrero.com
Expert Review of Neurotherapeutics
|May 29, 2008
Summary
Myasthenia gravis (MG) in women of childbearing age requires careful management during pregnancy. While unpredictable, MG can be effectively treated with safe therapies, necessitating close medical supervision.
Area of Science:
- Neurology
- Obstetrics
- Immunology
Background:
- Myasthenia gravis (MG) commonly affects women during their reproductive years.
- The disease course during pregnancy is unpredictable, with symptom exacerbation often occurring in early pregnancy and postpartum.
Purpose of the Study:
- To review the management of myasthenia gravis during pregnancy.
- To highlight safe and effective therapeutic options for pregnant individuals with MG.
- To emphasize the importance of multidisciplinary care.
Main Methods:
- Literature review of studies on myasthenia gravis management in pregnancy.
- Analysis of treatment protocols and outcomes.
- Discussion of anesthetic and obstetric considerations.
Main Results:
- Myasthenia gravis can be managed effectively during pregnancy using safe therapies.
- Anticholinesterase drugs are first-line treatment; corticosteroids, azathioprine, and cyclosporine A are options for refractory cases.
- Cesarean section is indicated only for obstetric reasons; epidural anesthesia is recommended.
Conclusions:
- Myasthenia gravis in pregnancy requires a multidisciplinary approach involving gynecologists and neurologists.
- Close monitoring is essential to manage potential life-threatening complications like respiratory insufficiency.
- Optimized management ensures favorable outcomes for both mother and child.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...